Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press34610.17650/1994-4098-2008-0-2-27-32MAMMOLOGY. TREATMENTМАММОЛОГИЯ. ЛЕЧЕНИЕCONTEMPORARY TRENDS IN THE TREATMENT OF METASTATIC BREAST CANCERСОВРЕМЕННЫЕ ТЕНДЕНЦИИ В ЛЕЧЕНИИ МЕТАСТАТИЧЕСКОГО РАКА МОЛОЧНОЙ ЖЕЛЕЗЫBorisovV. I.БорисовВ. И.
Russian Federation
Oncologic clinical dispensary No1, MoscowОнкологический клинический диспансер No1, Москва160520082273216092014160920142008https://ojrs.abvpress.ru/ojrs/article/view/346

Contemporary trends in the treatment of metastatic breast cancer are reviewed in the article: among them is so called targeted ther- apy. The main distinction of the targeted therapy is the maximum effect on tumor cell, at the same time minimum influence on nor- mal tissues is exerted. The author describes conservative approaches to the treatment of patients with metastatic breast cancer, the most effective schemes of drug therapy and basic prognostic factors affecting the choice of treatment tactics of patients with metasta- tic breast cancer. Besides, the randomized clinical trials addressing the current trends in the treatment of metatstatic breast cancer are evaluated.

СОВРЕМЕННЫЕ ТЕНДЕНЦИИ В ЛЕЧЕНИИ МЕТАСТАТИЧЕСКОГО РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ

1. Гарин А.М. Молекулярные мишени современной лекарственной терапии опухолей. ХI Российский онкологический конгресс. М.; 2007. с. 10—2.Гарин А.М. Молекулярные мишени современной лекарственной терапии опухолей. ХI Российский онкологический конгресс. М.; 2007. с. 10—2.2. Rueckert S., Ruehe I., Kahlert S. et al. Моноклональные антитела в лечении рака молочной железы: трастузумаб. Фармакотерапия 2006;2:14—24.Rueckert S., Ruehe I., Kahlert S. et al. Моноклональные антитела в лечении рака молочной железы: трастузумаб. Фармакотерапия 2006;2:14—24.3. Барышников А.Ю. Взаимоотношение опухоли и иммунной системы организма. Практ онкол 2003;3:127—31.Барышников А.Ю. Взаимоотношение опухоли и иммунной системы организма. Практ онкол 2003;3:127—31.4. Slamon D., Godolpbin W., Yones L. et al. Studies of the Her-2/neu proto- oncogene in human brest and ovarian cancer. Science 1989;244:797—12.Slamon D., Godolpbin W., Yones L. et al. Studies of the Her-2/neu proto- oncogene in human brest and ovarian cancer. Science 1989;244:797—12.5. Аничков Н.М. Биологические и клинико-морфологические аспекты учения о метастазировании злокачественных опухолей. Мед акад журн 2003;1:3—13.Аничков Н.М. Биологические и клинико-морфологические аспекты учения о метастазировании злокачественных опухолей. Мед акад журн 2003;1:3—13.6. Новик А.В., Моисеенко В.М. Теоретические предпосылки адъювантной терапии злокачественных опухолей. Практ онкол 2007;8(3):109—17.Новик А.В., Моисеенко В.М. Теоретические предпосылки адъювантной терапии злокачественных опухолей. Практ онкол 2007;8(3):109—17.7. Hart Y.R. Metastasis. Oxford of text- book of oncology. 2nd ed. Oxford University Press; 2002. p. 102—13.Hart Y.R. Metastasis. Oxford of text- book of oncology. 2nd ed. Oxford University Press; 2002. p. 102—13.8. Летягин В.Я. Опухоли молочной железы. Клиника, диагностика, лечение, прогноз. М.; 2000.Летягин В.Я. Опухоли молочной железы. Клиника, диагностика, лечение, прогноз. М.; 2000.9. Herbst R., Shin D. Monoclonal anti- bodies to target epidermal growth factor receptor-positive tumor. Cancer 2002;94:1593—611.Herbst R., Shin D. Monoclonal anti- bodies to target epidermal growth factor receptor-positive tumor. Cancer 2002;94:1593—611.10. Борисов В.И. Современные достижения в лечении рака молочной железы. Маммология 2006;(1):46—53.Борисов В.И. Современные достижения в лечении рака молочной железы. Маммология 2006;(1):46—53.11. Cobleigh M. et al. Health related quality life (HRQL) of patients with Her-2 overexpressing metastatic brest cancer (MBC) treated with herceptin (trastuzumab) as a single agent. Proc ASCO 1999;18:abstr 1613.Cobleigh M. et al. Health related quality life (HRQL) of patients with Her-2 overexpressing metastatic brest cancer (MBC) treated with herceptin (trastuzumab) as a single agent. Proc ASCO 1999;18:abstr 1613.12. Vogel C., Cobleigh M., Tripathy D. et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of Her-2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719—26.Vogel C., Cobleigh M., Tripathy D. et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of Her-2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719—26.13. Slamon D., Leytand-Yones B., Shak S. et al. Concurent administration of anti-Her-2 monoclonal antibody and first-line chemotherapy for Her-2 overex- pressing metastatic breast cancer. A phase III, multi-national randomized con- trolled trial. N Engl Med 2001;344:783— 92.Slamon D., Leytand-Yones B., Shak S. et al. Concurent administration of anti-Her-2 monoclonal antibody and first-line chemotherapy for Her-2 overex- pressing metastatic breast cancer. A phase III, multi-national randomized con- trolled trial. N Engl Med 2001;344:783— 92.14. Marty M., Cognetti F., Maraninchi D. et al. Randomised phase II trial of the efficacy and sadomised of trastuzumab with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast can- cer administered as first line treatment: M77001 Study Group. J Clin Oncol 2005;23(42):65—74.Marty M., Cognetti F., Maraninchi D. et al. Randomised phase II trial of the efficacy and sadomised of trastuzumab with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast can- cer administered as first line treatment: M77001 Study Group. J Clin Oncol 2005;23(42):65—74.15. Treatment Options in Early and Late-Stage Breast Cancer. 27 th Annual San Antonio Breast Cancer Symposium 2004; p. 47—9.Treatment Options in Early and Late-Stage Breast Cancer. 27 th Annual San Antonio Breast Cancer Symposium 2004; p. 47—9.16. Tauer K., Schwarzberg L. et al. Randomized phase II trial of two differ- ent shedules of carboplatin and paclitaxel trastuzumab as first-line treatment for metastatic cancer. ASCO 2006:abstr 10697.Tauer K., Schwarzberg L. et al. Randomized phase II trial of two differ- ent shedules of carboplatin and paclitaxel trastuzumab as first-line treatment for metastatic cancer. ASCO 2006:abstr 10697.17. Burstein H., Keshaviah A. et al. Trastuzumab and vinorelbin or taxane chemotherapy for Her-2 metastatic breast cancer: The TRAVIOTA study. ASCO 2006:abstr 650.Burstein H., Keshaviah A. et al. Trastuzumab and vinorelbin or taxane chemotherapy for Her-2 metastatic breast cancer: The TRAVIOTA study. ASCO 2006:abstr 650.18. Chan A., Petmzelka M., Untch M. et al. Long term survival of vinorelbine and trastuzumab as as first-line therapy for Her-2 positive metastatic breast can- cer. ASCO 2005:abstr 587.Chan A., Petmzelka M., Untch M. et al. Long term survival of vinorelbine and trastuzumab as as first-line therapy for Her-2 positive metastatic breast can- cer. ASCO 2005:abstr 587.19. Schaller G., Bangemann Y., Weber A. et al. Efficacy and safety of trastuzumab plus capecitabine in German multicentre phase II study of pretreated metastatic breast cancer. ASCO 2005:abstr 717.Schaller G., Bangemann Y., Weber A. et al. Efficacy and safety of trastuzumab plus capecitabine in German multicentre phase II study of pretreated metastatic breast cancer. ASCO 2005:abstr 717.20. Symon Z., Peyser A., Tzemach D. Selective delivery of doxorubicin to patients with brest carcinoma metastases by stealth liposomes. Cancer 1999;86:72—8.Symon Z., Peyser A., Tzemach D. Selective delivery of doxorubicin to patients with brest carcinoma metastases by stealth liposomes. Cancer 1999;86:72—8.21. Chia S., Clemons M., Martin L. et al. Pegylated liposomal doxorubicin and trastuzumab in Her-2 - overexpress- ing metastatic breast cancer: a multi-cen- ter phase II. Trial J Oncol 2006;24:2171—7.Chia S., Clemons M., Martin L. et al. Pegylated liposomal doxorubicin and trastuzumab in Her-2 - overexpress- ing metastatic breast cancer: a multi-cen- ter phase II. Trial J Oncol 2006;24:2171—7.22. Жукова Л.Г., Личиницер М.Р. Лапатиниб — ингибитор тирозинкиназ EGFR и Her-2: новые перспективы лечения больных с Her-2-положительным раком молочной железы (по материалам ASCO, 2007). Фарматека 2007;18:38— 41.Жукова Л.Г., Личиницер М.Р. Лапатиниб — ингибитор тирозинкиназ EGFR и Her-2: новые перспективы лечения больных с Her-2-положительным раком молочной железы (по материалам ASCO, 2007). Фарматека 2007;18:38— 41.23. Blackwell K., Kaplan E., Franco S. et al. A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2004;22(14 Suppl).Blackwell K., Kaplan E., Franco S. et al. A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2004;22(14 Suppl).24. Sherrill B., Allshouse A., Amonkar M. et al. A quality-adjusted time without symptoms or toxity (Q- TWIST) analysis comparing lapatinib plus capecitabine compared to capecitabine for metastatic breast cancer. Proc ASCO 2007:abstr 1026.Sherrill B., Allshouse A., Amonkar M. et al. A quality-adjusted time without symptoms or toxity (Q- TWIST) analysis comparing lapatinib plus capecitabine compared to capecitabine for metastatic breast cancer. Proc ASCO 2007:abstr 1026.25. Geyer C., Forster Y., Lindguist D. et al. Lapatinib plus capecitabine for Her-2-positive advanced breast cancer. N Engl J Med 2006;355:2733—43.Geyer C., Forster Y., Lindguist D. et al. Lapatinib plus capecitabine for Her-2-positive advanced breast cancer. N Engl J Med 2006;355:2733—43.26. Dileo A., Gomez H., Aziz Z. et al. Lapatinib with paclitaxel compared to paclitaxel as a first-line treatment for patients with metastatic breast cancer. A phase III randomized, double-blind study of 580 patients. Proc ASCO 2007:abstr 1011.Dileo A., Gomez H., Aziz Z. et al. Lapatinib with paclitaxel compared to paclitaxel as a first-line treatment for patients with metastatic breast cancer. A phase III randomized, double-blind study of 580 patients. Proc ASCO 2007:abstr 1011.27. Ferrara N., Gerber H. The biology of VEGF and its receptors. Nat Med 2003;9:669—76.Ferrara N., Gerber H. The biology of VEGF and its receptors. Nat Med 2003;9:669—76.28. Harmey Y., Bouchier-Hayes D. Vascular endothelial growth factor, a sur- vival factor to tumour cells: implications for anti-angiogenic therapy. Bioessays 2002;24:280—3.Harmey Y., Bouchier-Hayes D. Vascular endothelial growth factor, a sur- vival factor to tumour cells: implications for anti-angiogenic therapy. Bioessays 2002;24:280—3.29. Rugo H. Bevacizumab in the treat- ment of breast: rationale and current data. The Oncologist 2004;9(Suppl 1):43—9.Rugo H. Bevacizumab in the treat- ment of breast: rationale and current data. The Oncologist 2004;9(Suppl 1):43—9.30. Miller K., Rugo H. et al. Phase III trial of capecitabine plus bevacizumab versus capecitabine alone in women with metastatic breast cancer previously treat- ed with antracycline and taxane. Brest Cancer Res Treat 2002;76(Suppl 1):537.Miller K., Rugo H. et al. Phase III trial of capecitabine plus bevacizumab versus capecitabine alone in women with metastatic breast cancer previously treat- ed with antracycline and taxane. Brest Cancer Res Treat 2002;76(Suppl 1):537.31. Funes H. The role of bevacizumab in breast cancer. 18 Intern Congress on Anti Cancer Treatment. Paris;2007. p. 23,123—9.Funes H. The role of bevacizumab in breast cancer. 18 Intern Congress on Anti Cancer Treatment. Paris;2007. p. 23,123—9.